Living mapping and living systematic review of Covid-19 studies
Studies registered
2942
Registered studies
990
Randomized Trials (excluding Traditional Chinese Medicine trials)
556 RCTs recruiting
Results
17191
Records screened
17
Randomized Controlled Trials
5
Quasi-experimental studies
114
Observational studies
On June 2 we have screened 982 records and we have identified two new RCTs evaluating the efficacy and safety of interferon beta-1a and ruxolitinib .
The research mapping has been updated with 66 new registered RCTs identified in the WHO ICTRP on May 27, 2020.
Forest plots for the different treatment comparisons have been generated. The Evidence profile and Summary of Findings (SoF) table for most of the comparisons are also available online and the missing ones are currently being designed.
A living mapping of studies registered is now available: it is now possible to filter studies by type of pharmacological treatment, registration date, study aim, severity scale. An interactive map showing the clinical trials per country is also available. This data visualization was developed by a team from the LIRIS laboratory (CNRS/École Centrale de Lyon) in the context of a large collaboration with the CNRS. Several other teams from CNRS have offered their help for this project to contribute to the fight against Covid-19. As a result, more graphs and tables are currently being developed and will be soon available on our website.
To receive updates on our project and research findings, please subscribe to our weekly digest, we will share with you new RCT results and other interesting news.
Our main activities
We are performing a living mapping of ongoing research followed by a living network meta-analysis of study results as soon as they are available.
- We are searching and extracting data from RCTs registered in ICTRP once a week (the WHO updates its registry every Wednesday)
- We are mapping research with the help of a team of the LIRIS/CNRS laboratory that is performing a Data Visualization
- We are screening electronic databases (PubMed/Chinarxiv and MedRxiv) every day to identify results of RCTs and non-randomized-studies and case series.
- We are collecting data from all RCTs identified. The main characteristics of trials, including a complete description of the assessment of each risk of bias domain with support for judgement and forest plots are available here. Evidence synthesis is performed twice a week. Summary of findings (SoF) tables are currently being designed.
- We are contacting all investigators of ongoing trials to obtain the trial protocol and results as soon as available.
- Several databases of the reference list for modeling studies, observational studies, RCTs and quasi-experimental studies and studies we excluded from our systematic review are available online . Users of datasets published by the Covid-NMA project are required to acknowledge the source with an appropriate citation. We recommend using the following format: Authors. (Year). Dataset title [Data set]. Repository. DOI
Our process is summarized in this figure. For more information on our methods see our protocol here.
This study receives some funding from a grant from the ANR (Agence Nationale de la Recherche).